Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02397928
Recruitment Status : Completed
First Posted : March 25, 2015
Last Update Posted : September 25, 2018
Information provided by (Responsible Party):
NovoCure Ltd.

Brief Summary:
The study is a prospective, single arm, non-randomized, open label phase II trial, designed to study the safety and efficacy of a medical device, the NovoTTF-100L concomitant with Pemetrexed and cisplatin or carboplatin in Malignant Pleural Mesothelioma patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Condition or disease Intervention/treatment Phase
Malignant Pleural Mesothelioma Device: NovoTTF-100L device Drug: Pemetrexed Drug: Cisplatin or Carboplatin Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma
Actual Study Start Date : February 2015
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Arm Intervention/treatment
Experimental: TTFields concomitant to pemetrexed plus cisplatin/carboplatin
Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
Device: NovoTTF-100L device
Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
Other Name: TTFields

Drug: Pemetrexed
Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.

Drug: Cisplatin or Carboplatin
Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 1 year ]
  2. Response Rate [ Time Frame: 1 year ]
  3. Toxicity- incidence of adverse events [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Pathological or histological evidence of mesothelioma
  2. ≥ 18 years of age
  3. Not candidate for curative treatment (surgery or radiotherapy)
  4. At least 4 weeks since major surgery
  5. At least one measurable or evaluable lesion according to modified RECIST Criteria
  6. ECOG Performance Status of 0-1
  7. Life expectancy of at least 3 months
  8. Participants of childbearing age must use effective contraception as indicated by the investigator
  9. All subjects must sign written informed consent.
  10. Able to operate the NovoTTF-100L System independently or with the help of a caregiver

Exclusion Criteria:

  1. Patient candidate for surgery or radiotherapy with curative intent
  2. Previous chemotherapy or radiation
  3. Prior malignancy requiring anti-tumor treatment (apart from in-situ cervical cancer, in situ breast cancer, non-melanomatous skin cancers, or any malignancy for which treatment was received and there is no evidence of disease for at least 5 years) or concurrent malignancy
  4. Significant co-morbidities within 4 weeks prior to enrollment, resulting in the following laboratory findings:

    1. Significant liver function impairment:

      • AST or ALT > 3 times the upper limit of normal
      • Total bilirubin ≥ 1.5 times upper limit of normal
    2. Significant renal impairment (serum creatinine > 1.7 mg/dL)
    3. Coagulopathy (as evidenced by PT or APTT >1.5 times control in subjects not undergoing anticoagulation)
    4. Thrombocytopenia (platelet count < 100 x 10^3/μL)
    5. Neutropenia (absolute neutrophil count < 1.5 x 10^3/μL)
    6. Anemia (Hb < 10 g/dL)
    7. Severe acute infection
  5. Significant comorbidity which is expected to affect patient's prognosis or ability to receive the combined therapy:

    1. History of significant cardiovascular disease unless the disease is well controlled.

      Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation or dyspnea)

    2. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial
    3. Active infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol therapy
    4. History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements of the study or to provide consent
  6. Untreated brain metastases. Asymptomatic, pretreated brain metastases not requiring steroids are allowed
  7. Implanted pacemaker, defibrillator or other electrical medical devices
  8. Known allergies to medical adhesives or hydrogel
  9. Pregnant or breast feeding (all patients of childbearing potential must use effective contraception method during the entire period of the study based on the recommendation of the investigator or a gynecologist)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02397928

Layout table for location information
Antwerp University Hospital, Thoracic Oncology
Antwerp, Belgium
Goustave Roussy - Cancer Campus Grand Paris
Villejuif, France
Universitätsklinikum Halle (Saale)
Halle, Germany
A.S.O. "SS Antonio e Biagio e Cesare Arrigo"
Alessandria, Italy
Cliniche Humanitas Gavazzeni
Bergamo, Italy
Ospedale Villa Scassi
Genoa, Italy
Ospedaliera di Perugia
Perugia, Italy
Ospedaliero Universitaria Pisana
Pisa, Italy
Erasmus Mc
Rotterdam, Netherlands
Medical University Gdansk
Gdansk, Poland
Katedra i Klinika Onkologii Uniwersytetu Medycznegi im. Karola Marcinkowskiego w Poznaniu
Poznań, Poland
Klinika Nowotworów Pluca I Klatki Piersiowej
Warsaw, Poland
Vall d' Hebron Institute of Oncology (VHIO) Hospital Vall d'Hebron
Barcelona, Spain
Sponsors and Collaborators
NovoCure Ltd.
Layout table for investigator information
Principal Investigator: Giovanni Luca Ceresoli, MD Cliniche Humanitas Gavazzeni

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NovoCure Ltd. Identifier: NCT02397928    
Other Study ID Numbers: EF-23
First Posted: March 25, 2015    Key Record Dates
Last Update Posted: September 25, 2018
Last Verified: September 2018
Keywords provided by NovoCure Ltd.:
Malignant Pleural Mesothelioma
Minimal toxicity
Tumor Treating Fields
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma, Malignant
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Pleural Neoplasms
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors